GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Monte Rosa Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.66+0.92 (+9.45%)
Close on Oct 19, 2026
- Market cap
- $1.08B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Monte Rosa Therapeutics has not reported a dividend
No dividend per share appears in Monte Rosa Therapeutics's annual filings since fiscal 2019.